Go Pro
NASDAQ:IRMD

iRadimed (IRMD) Stock Price, News & Analysis

iRadimed logo
$86.95 -0.21 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$87.02 +0.08 (+0.09%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iRadimed Stock (NASDAQ:IRMD)

Advanced

Key Stats

Today's Range
$85.00
$87.21
50-Day Range
$87.16
$102.30
52-Week Range
$67.84
$107.90
Volume
142,683 shs
Average Volume
110,124 shs
Market Capitalization
$1.11 billion
P/E Ratio
48.58
Dividend Yield
0.92%
Price Target
$120.00
Consensus Rating
Moderate Buy

Company Overview

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites. These include safety filters, pressure transducers and patient temperature management systems, all optimized for operation within high-field magnetic environments. The company’s focus on reliability and regulatory compliance supports clinical use in hospitals, imaging centers and research institutions worldwide.

Founded in 1999 and headquartered in Winter Springs, Florida, iRadimed serves a global customer base through direct sales and international distributors across North America, Europe, Asia and Latin America. Its products are used in applications such as neuroimaging, cardiac imaging and oncology protocols where precise fluid delivery under MRI guidance is critical.

iRadimed completed its initial public offering in 2011 and is traded on the NASDAQ under the symbol IRMD. John B. Reininga, the company’s founder, serves as President and Chief Executive Officer, guiding product innovation and strategic growth in the specialized field of MRI-compatible medical devices.

AI Generated. May Contain Errors.

iRadimed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

IRMD MarketRank™: 

iRadimed scored higher than 65% of companies evaluated by MarketBeat, and ranked 293rd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iRadimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    iRadimed has a consensus price target of $120.00, representing about 38.0% upside from its current price of $86.95.

  • Amount of Analyst Coverage

    iRadimed has only been the subject of 1 research reports in the past 90 days.

  • Read more about iRadimed's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iRadimed is 48.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.57.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iRadimed is 48.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.86.

  • Price to Book Value per Share Ratio

    iRadimed has a P/B Ratio of 10.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about iRadimed's valuation and earnings.
  • Percentage of Shares Shorted

    8.01% of the float of iRadimed has been sold short.
  • Short Interest Ratio / Days to Cover

    iRadimed has a short interest ratio ("days to cover") of 5.77.
  • Change versus previous month

    Short interest in iRadimed has recently decreased by 5.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    iRadimed has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    iRadimed has only been increasing its dividend for 1 years.

  • Dividend Coverage

    The dividend payout ratio of iRadimed is 44.69%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about iRadimed's dividend.
  • News Sentiment

    iRadimed has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for iRadimed this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for IRMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $883,750.00 in company stock.

  • Percentage Held by Insiders

    34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about iRadimed's insider trading history.
Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRMD Stock News Headlines

They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
iRadimed (NASDAQ:IRMD) Rating Lowered to "Hold" at Wall Street Zen
See More Headlines

IRMD Stock Analysis - Frequently Asked Questions

iRadimed's stock was trading at $97.28 at the beginning of 2026. Since then, IRMD stock has decreased by 10.6% and is now trading at $86.95.

iRadimed Corporation (NASDAQ:IRMD) posted its quarterly earnings results on Friday, July, 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. The medical equipment provider earned $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a trailing twelve-month return on equity of 23.45%.
Read the conference call transcript
.

iRadimed (IRMD) raised $13 million in an IPO on Wednesday, July 16th 2014. The company issued 2,016,000 shares at $6.25 per share.

Top institutional shareholders of iRadimed include BlackRock Inc. (7.57%), Ranger Investment Management L.P. (0.77%), Bank of New York Mellon Corp (0.59%) and Algert Global LLC (0.57%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn.
View institutional ownership trends
.

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

Record date for 5/29 Dividend
5/15/2026
Ex-Dividend for 5/29 Dividend
5/15/2026
Dividend Payable
5/29/2026
Last Earnings
7/31/2026
Today
8/14/2026
Record date for 8/28 Dividend
8/14/2026
Ex-Dividend for 8/28 Dividend
8/14/2026
Dividend Payable
8/28/2026
Next Earnings (Estimated)
11/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IRMD
CIK
1325618
Employees
110
Year Founded
2004

Price Target and Rating

High Price Target
$120.00
Low Price Target
$120.00
Potential Upside/Downside
+38.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.79
Trailing P/E Ratio
48.58
Forward P/E Ratio
43.91
P/E Growth
N/A
Net Income
$22.48 million
Net Margins
26.70%
Pretax Margin
34.45%
Return on Equity
23.45%
Return on Assets
20.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.46
Quick Ratio
8.13

Sales & Book Value

Annual Sales
$86.34 million
Price / Sales
12.88
Cash Flow
$1.85 per share
Price / Cash Flow
47.02
Book Value
$7.96 per share
Price / Book
10.92

Miscellaneous

Outstanding Shares
12,787,000
Free Float
8,363,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
0.90

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:IRMD) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners